Menu Back toSpeakers

3rd ICH Information Day


  • Martin  Harvey Allchurch, LLM

    Martin Harvey Allchurch, LLM

    • Governance and Board Relations Manager, External Relations Team
    • Unitaid, Netherlands

    Martin Harvey Allchurch serves as Principal International Affairs Officer for the European Medicines Agency (EMA), EU. He first joined the EMA legal team after serving as a European affairs consultant in Brussels. He subsequently headed the Office of the Executive Director, served as Head of Communication, and then moved to the Agency's International Affairs team. Mr. Harvey Allchurch has served on the DIA Advisory Council for Europe, Middle East, and Africa; and as program advisor for the DIA EuroMeeting and Global Annual Meeting. He earned Law degrees from the University of Dundee (UK) and Vrije Universiteit Brussels (Belgium).

  • Lenita  Lindström-Gommers, LLM

    Lenita Lindström-Gommers, LLM

    • ICH Assembly Chair and Senior Expert, European Commission
    • European Commission, Belgium

    ICH Assembly Chair Senior Policy Officer in DG SANTE/European Commission dealing with international relations in the field of pharmaceuticals

  • Tomas  Salmonson, DrMed, PhD

    Tomas Salmonson, DrMed, PhD

    • Partner
    • Consilium Salmonson and Hemmings, Sweden

    Tomas Salmonson, M.Sc., PhD, brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency in Uppsala, Sweden. He has been a member of the Committee for Medicinal Products for Human Use (CHMP) for more than 12 years. In 2012, Dr Salmonson was elected chair of the CHMP; he was Vice chair of the CHMP from 2007 till 2012. Tomas has been DIA Advisory Council of Europe Member during 1996-2002 and a speaker in over 20 DIA Events.

  • Toshiyoshi  Tominaga, PhD

    Toshiyoshi Tominaga, PhD

    • Senior Advisor
    • Japan Self-Medication Industry, Japan

    Dr. Tominaga is Associate Executive Director for International Programs. He supervises the overall strategy and conduct of international operations by PMDA. He joined MHLW after acquired PhD from Faculty of Pharmaceutical Sciences, the University of Tokyo. As a career official, he experienced positions dealing with narcotics control, R&D enhancement, and so on. His international experience includes graduate study at Harvard School of Public Health, stay in Vienna as a diplomat, and at USFDA.

  • Steven  Teerenstra, PhD, MSc

    Steven Teerenstra, PhD, MSc

    • Statistician
    • Medicines Evaluation Board, Netherlands

  • Corina Dana Dota, MD

    Corina Dana Dota, MD

    • AZ ECG Centre Director
    • AstraZeneca R&D Molndal, Sweden

  • Jan Willem  van der Laan, PhD

    Jan Willem van der Laan, PhD

    • Senior Assessor Pharmacology and Toxicology
    • Medicines Evaluation Board, Netherlands

    In 1980 Jan Willem van der Laan joint the National Institute for Public Health and the Environment (RIVM, Bilthoven) as a biochemist and pharmacologist on CNS targets. In 1990 is he assessor Pharmacology and Toxicology of Human Pharmaceuticals at the and later, since 2011 directly for the Medicines Evaluation Board, located in Utrecht, the Netherlands. He is chair of the EMA/CHMP Safety Working Party since 2012. His contributions to the International Council on Harmonization started in 1993 on Carcinogenicity Testing. In 2012 the discussions on this topic have been restarted to reduce the number of 2-yr studies in rodents, and Jan Willem is Regulatory Chair on this process.

  • Filip  Mussen, PhD

    Filip Mussen, PhD

    • Vice President, Regional Regulatory Affairs
    • Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium

    Filip Mussen is Vice President, Regional Regulatory Affairs at Janssen R&D and responsible for regulatory affairs in Asia-Pacific, Europe, Middle East, Africa, and Latin-America. Filip joined Johnson & Johnson in 2008. In 2011 he became the Head of the Global Labeling CoE. Previously he worked at Merck & Co. in Regulatory Affairs. Filip obtained a Master of Science degree from the University of Gent (Belgium), and his PhD from Cardiff University (UK).

  • Dawn  Ronan

    Dawn Ronan

    • Regulatory & Scientific Manager
    • ICH Secretariat, Switzerland

Contact us

Registration Questions

Send Email
+41 61 225 51 51

Agenda and Logistics

Send Email
+41 61 225 51 65